Treatment of the antiphospholipid syndrome

The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent rec...

Full description

Saved in:
Bibliographic Details
Published in:Autoimmunity highlights 2014-06, Vol.5 (1), p.1-7
Main Author: Galli, Monica
Format: Article
Language:English
Subjects:
Antiphospholipid antibodies
Antiphospholipid syndrome
Aspirin
Autografts
Corticosteroids
Heparin
Hydroxychloroquine
Molecular weight
Monoclonal antibodies
Review
Rituximab
Stem cell transplantation
Thrombosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed.
ISSN:2038-0305
2038-3274
DOI:10.1007/s13317-013-0056-5